Latest Insider Transactions at Merck & Co., Inc. (MRK)
This section provides a real-time view of insider transactions for Merck & Co., Inc. (MRK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Merck & Co., Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Merck & Co., Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 01
2022
|
Lisa Le Cointe Cephas SVP Chief Ethics & Com Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
220
-7.21%
|
$19,360
$88.69 P/Share
|
|
May 01
2022
|
Lisa Le Cointe Cephas SVP Chief Ethics & Com Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
640
+17.33%
|
$56,320
$88.69 P/Share
|
|
Feb 24
2022
|
Robert M Davis Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
29,896
+10.77%
|
$2,182,408
$73.51 P/Share
|
|
Feb 24
2022
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Grant, award, or other acquisition
|
Direct |
19,836
+14.93%
|
$1,448,028
$73.51 P/Share
|
|
Feb 24
2022
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Grant, award, or other acquisition
|
Direct |
15,966
+10.65%
|
$1,165,518
$73.51 P/Share
|
|
Feb 24
2022
|
Kenneth C Frazier Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
119,488
+14.47%
|
$8,722,624
$73.51 P/Share
|
|
Feb 24
2022
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,550
+16.39%
|
$697,150
$73.51 P/Share
|
|
Feb 24
2022
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Grant, award, or other acquisition
|
Direct |
3,478
+8.13%
|
$253,894
$73.51 P/Share
|
|
Feb 24
2022
|
Michael A Klobuchar EVP - Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,994
+17.56%
|
$218,562
$73.51 P/Share
|
|
Feb 24
2022
|
Dean Y Li Executive VP & President, MRL |
BUY
Grant, award, or other acquisition
|
Direct |
3,023
+16.35%
|
$220,679
$73.51 P/Share
|
|
Feb 24
2022
|
Caroline Litchfield EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,429
+8.38%
|
$177,317
$73.51 P/Share
|
|
Feb 24
2022
|
Steven Mizell EVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,571
+26.63%
|
$1,063,683
$73.51 P/Share
|
|
Feb 24
2022
|
David Michael Williams EVP,Chief Info&Digital Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,660
+16.17%
|
$121,180
$73.51 P/Share
|
|
Feb 24
2022
|
Jennifer Zachary EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
18,420
+25.64%
|
$1,344,660
$73.51 P/Share
|
|
Feb 10
2022
|
David Michael Williams EVP,Chief Info&Digital Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
477
-6.43%
|
$36,252
$76.53 P/Share
|
|
Feb 10
2022
|
David Michael Williams EVP,Chief Info&Digital Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,202
+13.94%
|
$91,352
$76.53 P/Share
|
|
Nov 09
2021
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
663,881
-27.76%
|
$54,438,242
$82.73 P/Share
|
|
Nov 09
2021
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
663,881
+34.68%
|
-
|
|
Nov 04
2021
|
Caroline Litchfield EVP & CFO |
SELL
Open market or private sale
|
Direct |
18,335
-43.19%
|
$1,668,485
$91.0 P/Share
|
|
Nov 04
2021
|
Caroline Litchfield EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,683
+34.83%
|
-
|
|
Nov 04
2021
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
SELL
Open market or private sale
|
Direct |
29,782
-20.3%
|
$2,680,380
$90.4 P/Share
|
|
Nov 04
2021
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Exercise of conversion of derivative security
|
Direct |
29,782
+16.87%
|
-
|
|
Nov 03
2021
|
Rita A Karachun Sr. VP Fince-Global Controller |
SELL
Open market or private sale
|
Direct |
25,000
-41.12%
|
$2,200,000
$88.45 P/Share
|
|
Nov 03
2021
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+29.14%
|
-
|
|
Nov 01
2021
|
Julie L. Gerberding EVP, Chief Patient Officer |
SELL
Open market or private sale
|
Direct |
96,270
-71.08%
|
$8,375,490
$87.91 P/Share
|
|
Nov 01
2021
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
96,270
+18.96%
|
-
|
|
Nov 01
2021
|
Frank Clyburn EVP & Pres ? Human Health |
SELL
Open market or private sale
|
Direct |
39,762
-29.05%
|
$3,459,294
$87.87 P/Share
|
|
Nov 01
2021
|
Frank Clyburn EVP & Pres ? Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
39,762
+13.6%
|
-
|
|
Oct 30
2021
|
Steven Mizell EVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,323
-8.33%
|
$204,424
$88.05 P/Share
|
|
Oct 30
2021
|
Steven Mizell EVP, Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,715
+14.46%
|
$414,920
$88.05 P/Share
|
|
Oct 30
2021
|
Frank Clyburn EVP & Pres ? Human Health |
SELL
Payment of exercise price or tax liability
|
Direct |
1,162
-1.18%
|
$102,256
$88.05 P/Share
|
|
Oct 30
2021
|
Frank Clyburn EVP & Pres ? Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
2,358
+2.34%
|
$207,504
$88.05 P/Share
|
|
Oct 29
2021
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
SELL
Open market or private sale
|
Direct |
135,405
-53.66%
|
$11,780,235
$87.56 P/Share
|
|
Oct 29
2021
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Exercise of conversion of derivative security
|
Direct |
135,405
+23.79%
|
-
|
|
Oct 29
2021
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
SELL
Open market or private sale
|
Direct |
24,619
-20.91%
|
$2,141,853
$87.32 P/Share
|
|
Oct 29
2021
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Exercise of conversion of derivative security
|
Direct |
24,619
+17.29%
|
-
|
|
May 10
2021
|
Frank Clyburn EVP & Pres ? Human Health |
SELL
Open market or private sale
|
Direct |
19,324
-17.0%
|
$1,507,272
$78.32 P/Share
|
|
May 10
2021
|
Frank Clyburn EVP & Pres ? Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
19,324
+14.53%
|
-
|
|
May 04
2021
|
Frank Clyburn EVP & Pres ? Human Health |
SELL
Payment of exercise price or tax liability
|
Direct |
939
-0.99%
|
$70,425
$75.98 P/Share
|
|
May 04
2021
|
Frank Clyburn EVP & Pres ? Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
1,906
+1.96%
|
$142,950
$75.98 P/Share
|
|
May 04
2021
|
Lisa Le Cointe Cephas SVP Chief Ethics & Com Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
238
-9.11%
|
$17,850
$75.98 P/Share
|
|
May 04
2021
|
Lisa Le Cointe Cephas SVP Chief Ethics & Com Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
694
+20.99%
|
$52,050
$75.98 P/Share
|
|
May 04
2021
|
Jennifer Zachary EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,843
-7.69%
|
$213,225
$75.98 P/Share
|
|
May 04
2021
|
Jennifer Zachary EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,772
+13.5%
|
$432,900
$75.98 P/Share
|
|
May 04
2021
|
Dean Y Li Executive VP & President, MRL |
SELL
Payment of exercise price or tax liability
|
Direct |
238
-1.9%
|
$17,850
$75.98 P/Share
|
|
May 04
2021
|
Dean Y Li Executive VP & President, MRL |
BUY
Exercise of conversion of derivative security
|
Direct |
694
+5.24%
|
$52,050
$75.98 P/Share
|
|
May 04
2021
|
Caroline Litchfield EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
489
-2.42%
|
$36,675
$75.98 P/Share
|
|
May 04
2021
|
Caroline Litchfield EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,039
+4.89%
|
$77,925
$75.98 P/Share
|
|
May 04
2021
|
Rita A Karachun Sr. VP Fince-Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
416
-1.15%
|
$31,200
$75.98 P/Share
|
|
May 04
2021
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
1,212
+3.24%
|
$90,900
$75.98 P/Share
|